Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for reversal of rocuronium-induced neuromuscular blockade in infants undergoing Kasai operation
PACTR201907522427588Phase 2Not yet recruiting
- Sponsor
- National Liver Institute
- Start
- Apr 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of Sugammadex, neostigmine and rocuronium in biliary atresia (2 arms), sponsored by National Liver Institute. Primary endpoint: Time to recovery of train-of-four ratio to 0.9. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
Sugammadexneostigminerocuronium
03
Conditions
biliary atresia
Beyond the preview
Go deeper on PACTR201907522427588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201907522427588.